31 Oct
2020

Despite apparent convergence, life sciences and high-tech IP management will remain worlds apart

The growing influence of high-tech in the life sciences industry has led some to speculate that the IP strategies used in both sectors will begin to converge, but, argues Adam Houldsworth, for several reasons that is unlikely to happen

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth